Drug Profile
RP 3128
Alternative Names: RP-3128Latest Information Update: 22 Feb 2022
Price :
$50
*
At a glance
- Originator Rhizen Pharmaceuticals
- Class Antiasthmatics; Small molecules
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Atopic dermatitis; Inflammatory bowel diseases; Ulcerative colitis
- Discontinued Asthma
Most Recent Events
- 22 Feb 2022 Discontinued - Phase-I/II for Asthma in Canada (PO) (Rhizen Pharmaceuticals pipeline, February 2022)
- 22 Feb 2022 Phase-I clinical trials in Atopic dermatitis (PO) (Rhizen Pharmaceuticals pipeline, February 2022)
- 22 Feb 2022 Phase-I clinical trials in Inflammatory bowel diseases (PO) (Rhizen Pharmaceuticals pipeline, February 2022)